BWM
MCRB icon

Baystate Wealth Management’s Seres Therapeutics MCRB Stock Holding History

Baystate Wealth Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5
Closed -$1K – 673
2016
Q4 		$1K Buy
+5
New +$1.09K ﹤0.01% 415

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Baystate Wealth Management's MCRB Position: Q1 2017 in Review

Baystate Wealth Management sold out of Seres Therapeutics (MCRB) in Q1 2017, closing a stake of 5 shares — an estimated $1K sold.

Baystate Wealth Management first reported a position in MCRB in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 79 funds tracked by Wall St. Rank hold MCRB as of Q1 2017.

  • Baystate Wealth Management reported no remaining Seres Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Baystate Wealth Management sold 5 Seres Therapeutics shares in Q1 2017, an estimated $1K.
  • Baystate Wealth Management first reported a position in Seres Therapeutics in Q4 2016 and held it in 1 quarter.
  • Baystate Wealth Management's Seres Therapeutics position peaked at $1K in Q4 2016.
  • 79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2017.

Based on Baystate Wealth Management's 13F filing for Q1 2017, filed 25 Apr 2017.